Special Issue

Advances in Thoracic Oncology

Message from the Guest Editors

In this Special Issue of Cancers, we focus on "Advances in Thoracic Oncology" and provide an overview of recent developments in the diagnosis and treatment of lung cancer, thymic epithelial tumors and mesothelioma. The landscape of thoracic oncology has changed significantly during the last decade. Due to advances in biomarker testing, medical oncologists are able to provide personalized therapy for lung cancer patients consisting of targeted therapies and immune checkpoint inhibitors. This also has an impact on surgical management. Specifically for thoracic surgeons, new insights have been obtained in the role of sublobar resection. For radiation oncologists, newer treatment modalities have become available, allowing more precise delivery of radiotherapy, limiting collateral damage to surrounding vital organs in the chest. These are fascinating times for all specialists dealing with thoracic oncology and we sincerely hope you will find useful, updated information in this Special Issue. As we are currently witnessing the significant results of new therapeutic modalities, the main goal still remains to improve long-term outcomes in patients with thoracic malignancies.

Guest Editors

Prof. Dr. Paul Van Schil

Department of Thoracic and Vascular Surgery, Antwerp University and Antwerp University Hospital, Edegem, Belgium

Prof. Dr. Jan Van Meerbeeck

Department of Thoracic Oncology, Antwerp University and Antwerp University Hospital, Edegem, Belgium

Deadline for manuscript submissions

closed (15 August 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/136024

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

